Chargement en cours...

Priority setting at the clinical level: the case of nusinersen and the Norwegian national expert group

BACKGROUND: Nusinersen is one of an increasing number of new, expensive orphan drugs to receive authorization. These drugs strain public healthcare budgets and challenge principles for resource allocation. Nusinersen was introduced in the Norwegian public healthcare system in 2018. A national expert...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Med Ethics
Auteurs principaux: Magelssen, Morten, Rasmussen, Magnhild, Wallace, Sean, Førde, Reidun
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2021
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8094497/
https://ncbi.nlm.nih.gov/pubmed/33947377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12910-021-00623-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!